IL13 and asthma: Currently, the FDA has approved biologics targeting typical Type 2 cytokines and their receptors (such as the anti‐IL‐5 monoclonal antibody mepolizumab, anti‐IL‐13 monoclonal antibody lebrikizumab, and anti‐IL‐4R monoclonal antibody dupilumab) for clinical use in treating severe asthma driven by Type 2 inflammation.